<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Liraglutide: what changed | Grey Peptides</title>
    <link>https://greypeptides.com/changes/#e-liraglutide</link>
    <atom:link href="https://greypeptides.com/changes/liraglutide.xml" rel="self" type="application/rss+xml" />
    <description>News, regulatory alerts, corrections and new guides about Liraglutide on Grey Peptides, newest first.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 04 Nov 2026 12:00:00 +0000</lastBuildDate>
    <ttl>1440</ttl>
    <item>
      <title>News: A Gene Variant Linked to a Weaker Response to GLP-1 Drugs: What the PAM Study Found</title>
      <link>https://greypeptides.com/news/pam-gene-variants-glp1-response/</link>
      <guid isPermaLink="false">greypeptides-changes-liraglutide-news-pam-gene-variants-glp1-response</guid>
      <pubDate>Wed, 04 Nov 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>A Gene Variant Linked to a Weaker Response to GLP-1 Drugs: What the PAM Study Found</description>
    </item>
    <item>
      <title>News: Saxenda Is Being Discontinued, and Rybelsus Tablets Are Being Replaced</title>
      <link>https://greypeptides.com/news/saxenda-discontinued-rybelsus-replaced/</link>
      <guid isPermaLink="false">greypeptides-changes-liraglutide-news-saxenda-discontinued-rybelsus-replaced</guid>
      <pubDate>Mon, 05 Oct 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>Saxenda Is Being Discontinued, and Rybelsus Tablets Are Being Replaced</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA extended the comment period on its proposal not to put semaglutide, tirzepatide or liraglutide on the 503B bulks list by 30 days, to July 30, 2026 (91 FR 38719).</title>
      <link>https://greypeptides.com/regulatory/alerts/#503b-glp1-comment-extended</link>
      <guid isPermaLink="false">greypeptides-changes-liraglutide-alert-503b-glp1-comment-extended</guid>
      <pubDate>Fri, 26 Jun 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>Comments are closed. As of November 2, 2026 the Federal Register held no final determination: the June 26 extension is the newest document in docket FDA-2018-N-3240.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA proposed not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list (91 FR 23431, docket FDA-2018-N-3240).</title>
      <link>https://greypeptides.com/regulatory/alerts/#503b-glp1-proposal</link>
      <guid isPermaLink="false">greypeptides-changes-liraglutide-alert-503b-glp1-proposal</guid>
      <pubDate>Fri, 01 May 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>A proposal, not a rule. It concerns outsourcing facilities compounding from bulk when there is no shortage; the three were never on the list, so nothing was removed.</description>
    </item>
  </channel>
</rss>
